BioCentury
ARTICLE | Clinical News

APD421: Phase III started

May 4, 2015 7:00 AM UTC

Acacia began a double-blind, placebo-controlled, international Phase III trial to evaluate a single dose of IV APD421 plus standard anti-emetic treatment in up to 1,200 high-risk patients ages >=18 un...